Abstract:Patients with anaplastic lymphoma kinase (ALK) fusion lung adenocarcinoma may develop drug resistance after treatment with ALK-tyrosine kinase inhibitor (ALK-TKI), and the mechanisms of this resistance are not yet fully defined. The Affiliated Hospital of Zunyi Medical University admitted a patient who was resistant to ALK fusion after ALK-TKI treatment, leading to disease progression and subsequent biopsy indicating a transformation to small cell lung cancer in September 2021. The patient, a 54-year-old female, initially presented with symptoms of cough, sputum production, and chest pain for 4 months. Chest CT showed a neoplastic lesion in the posterior segment of the right upper lobe to right lower lobe with obstructive pneumonia, metastasis in the right lower lobe, increased and enlarged mediastinal and right hilar lymph nodes, and thickening of the right hilar soft tissue. Bronchoscopy and pathological biopsy confirmed the diagnosis of lung adenocarcinoma. The results of next-generation sequencing indicated that echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) fusion is associated with tumor protein 53 (TP53) and retinoblastoma 1 (RB1) gene mutations. The patient received second-generation ALK-TKI aletinib, achieving a progression-free survival of 11 months before disease progression suggested aletinib resistance. Subsequently, the third-generation ALK-TKI lorlatinib administered for one month without efficacy, resulting in rapid systemic disease progression. The neuron specific enolase (NSE) was significantly increased, and the patient developed new pleural, pericardial, intracranial, liver, and multiple bone metastases occurred in a short period. A second biopsy indicated small cell lung cancer. Modification of treatment regimen to chemotherapy combined with immunotherapy proved effective. The mechanisms of drug resistance of ALK-TKI treatment for advanced non-small cell lung cancer with ALK fusion are complex, and small cell transformation of pathological type is one such mechanism, although rare. Concurrent TP53 and RB1 gene mutations may be characteristic of this transformation. Elevated NSE can serve as a predictive serum marker for adenocarcinoma transforming to small cell carcinoma. Timely re-biopsy and selection of subsequent treatments based on different resistance mechanisms are crucial for comprehensive disease management.

Eml4-Alk Induces Epithelial-Mesenchymal Transition Consistent with Cancer Stem Cell Properties in H1299 Non-Small Cell Lung Cancer Cells

The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes

EMLA-ALK fusion gene in non-small cell lung cancer

Mir-145-5p Inhibits Epithelial-Mesenchymal Transition Via the JNK Signaling Pathway by Targeting MAP3K1 in Non-Small Cell Lung Cancer Cells.

A Case of Small Cell Lung Carcinoma Harboring an EML4–ALK Fusion with Partial Response to Crizotinib

EML4-ALK Fusions Drive Lung Adeno-to-squamous Transition Through JAK-STAT Activation.

The Fusion Circular RNA F-circEA1 Promotes Non-small Cell Lung Carcinoma Progression through ALK Downstream Signaling

Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer

Phase Separation of EML4–ALK in Firing Downstream Signaling and Promoting Lung Tumorigenesis

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Initial analysis of EML4-ALK fusion gene in non-small cell lung cancer

ALK fusion small cell transformation of lung adenocarcinoma: A case report and literature review

F-circEA1 regulates cell proliferation and apoptosis through ALK downstream signaling pathway in non-small cell lung cancer

Eml4-Alk Rearrangement And Its Clinical Significance In Chinese Patients With Advanced Non-Small Cell Lung Cancer

EML4-ALK Translocation is Associated with Early Onset of Disease and Other Clinicopathological Features in Chinese Female Never-Smokers with Non-Small-cell Lung Cancer.

Egfr-Tki Benefit for Nsclc Patients with Eml4-Alk Rearrangement

ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression

EML4‐ALK biology and drug resistance in Non‐Small Cell Lung Cancer: a new phase of discoveries

Mutant p53 achieves function by regulating EGR1 to induce epithelial mesenchymal transition

Data from NPM–ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation

Ott_a_335736 5385..5389